Particle.news
Download on the App Store
9 ARTICLES
·
6d ago

ACC/AHA Overhaul Cholesterol Care With Earlier Screening, New Risk Tool and Clear LDL Targets

The joint guideline pivots to earlier-life prevention with a new risk calculator plus explicit LDL targets.

Lipitor(atorvastain calcium) tablets made by Pfizer and distributed by Parke-Davis are seen November 30, 2011 in Washington, DC. Pfizer's patent on the best-selling drug of all-time, the cholesterol-lowering medication Lipitor, expired on November 30, 2011, opening the path to generic competitors for America's most popular medication. Lipitor came on the market in 1997, and has raked in some $100 billion for Pfizer even in a crowded market that includes various other cholesterol-lowering statins, many of which have already gone generic. In the United States, anti-cholesterol drugs account for 255 million prescriptions a year, and about nine million people are taking Lipitor. AFP Photo/Paul J. Richards (Photo by Paul J. RICHARDS / AFP) (Photo by PAUL J. RICHARDS/AFP via Getty Images)
Image
Image
Representational image. | The guidelines aim at early detection and treatment of dyslipidemia—unhealthy levels of fats in the blood.

Overview

  • Major U.S. cardiology societies published a unified dyslipidemia guideline in JACC and Circulation that expands routine ASCVD risk assessment to ages 30–79 using the PREVENT‑ASCVD equations for 10‑ and 30‑year risk.
  • The update lowers the bar for treatment consideration, with lipid‑lowering therapy recommended around a 5% 10‑year risk and potential initiation in the 30s when risk factors persist despite lifestyle change.
  • Specific LDL‑C goals return: under 100 mg/dL for primary prevention, under 70 mg/dL for high‑risk individuals, and under 55 mg/dL for those with very high risk or established ASCVD.
  • Risk refinement now includes a one‑time adult Lp(a) measurement, selective apoB testing, and coronary artery calcium scoring to guide the intensity of therapy.
  • Statins remain first‑line, with ezetimibe, bempedoic acid, and PCSK9 inhibitors as add‑ons when needed, and the guidance reiterates pediatric screening at ages 9–11, or starting at age 2 for children with strong familial risk.